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Purpose: The Adolescent Medicine Trials Network Protocol 113 (ATN113) is an open-label, 
multi-site demonstration project and phase II safety study of HIV pre-exposure prophylaxis with 
15-17 year old young men who have sex with men that requires adolescent consent for 
participation. The purpose of this study was to examine factors related to the process by which 
Institutional Review Boards (IRBs) and researchers made decisions regarding whether to 
approve and implement ATN113, so as to inform future biomedical HIV prevention research 
with high-risk adolescent populations. 
 
Methods: Participants included seventeen researchers at thirteen sites in twelve states 
considering ATN113 implementation. Qualitative descriptive methods were used. Data sources 
included interviews and documents generated during the initiation process.  
 
Results: A common process for initiating ATN113 emerged, and informants described how they 
identified and addressed practical, ethical and legal challenges that arose. Informants described 
the process as responding to the protocol, preparing for IRB submission, abstaining from or 
proceeding with submission, responding to IRB concerns and reacting to the outcomes. A 
complex array of factors impacting approval and implementation were identified; and ATN113 
was ultimately implemented in 7 of 13 sites. Informants also reflected on lessons learned that 




Conclusions: The results illustrate factors for consideration in determining whether to 
implement such trials, demonstrate that such protocols have the potential to be approved, and 
highlight a need for clearer standards regarding biomedical HIV prevention research with high-
risk adolescent populations. 
 
IMPLICATIONS AND CONTRIBUTION 
This study illustrates the complexity of practical, legal and ethical factors that researchers and 
IRB members must consider in determining whether to implement biomedical HIV prevention 
trials with high-risk adolescent populations; demonstrates that such protocols have the potential 




An emerging approach to the prevention of Human Immunodeficiency Virus (HIV) transmission 
is Pre-Exposure Chemoprophylaxis (PrEP) using daily oral doses of the antiretroviral drug 
combination Emtricitabine/Tenofovir (FTC/TDF). FTC/TDF PrEP has been approved by the 
U.S. Food and Drug Administration (FDA) for high-risk adult populations.1,2 Although young 
men who have sex with men (YMSM) are disproportionately affected by HIV,3,4 minor youth 
were excluded from clinical trials informing this FDA indication for use. 
 
Minor adolescents are frequently excluded from biomedical HIV prevention research due to the 
legal and ethical complexity of including them. Researchers often have ethical concerns about 
adolescent vulnerability and capacity for research-related decision-making, and legal concerns 
about navigating laws that may require parental consent.5-8 Mandates for parental consent pose 
even greater barriers to recruitment in studies that address sensitive issues such as sexuality and 
sexual practices.7-9 In the case of YMSM, for example, youth may be unwilling to participate in a 
study in which the informed consent process is likely to result in their sexual status and/or sexual 
activity being revealed to their family, potentially resulting in rejection or violence.10,11 In certain 
circumstances such as these, ethical considerations supporting adolescent inclusion in research 
(e.g., the critical importance of clinical trials data on PrEP safety for YMSM or the high 
vulnerability of YMSM to HIV) may overshadow those requiring parental consent.5,8,12   
 
Federal regulations governing research conducted with FDA oversight stipulate parental consent 
for research with minors; and waiver of parental consent is therefore not permitted.13,14 However, 
in limited circumstances where adolescents meet criteria for emancipation, are considered 
“mature minors,” or are otherwise allowed to consent on their own behalf to the treatment or care 
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being studied under state law, they may legally be permitted to consent to the research on their 
own behalf without parental consent .8,15 Local Institutional Review Boards (IRBs) routinely 
determine whether the consent procedures proposed in a study are both ethically justified and 
compliant with state and federal law.16 No biomedical HIV prevention trial has previously been 
conducted in the United States among adolescents aged 15 to 17 years without parental consent; 
and the process by which researchers and IRBs undertake the difficult task of reviewing and 
implementing such protocols with high-risk minor populations has never been examined. 
 
The ATN and Protocol 113 
The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN), funded primarily 
by the National Institute of Child Health and Human Development, conducts HIV prevention and 
treatment research among youth aged 12-24 years in 14 clinical sites and surrounding 
communities. The challenge of balancing the legal and ethical justifications for and against 
minor self-consent was addressed by the ATN during a Phase II PrEP safety study (ATN 
Protocol 113, subsequently identified as ATN113) for 15-17 year old YMSM. Motivated by the 
reality that FTC/TDF is likely to be used off-label for PrEP purposes among YMSM, the ATN 
sought to obtain safety data for this indication, including assessments of patterns of use, 
adherence, and changes in sexual risk and protective behaviors. The protocol also included an 
efficacious behavioral risk reduction intervention to address potential risk compensation 
associated with PrEP.  
 
ATN113 was open to all sites, based on a common protocol that was approved by experts within 
the ATN and the National Institutes of Health. Additional opinions regarding adolescent self-
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consent were provided by the ATN Ethics Advisory Panel, the Office of Human Research 
Protection and the FDA. These bodies concluded that it was legally and ethically appropriate for 
minor adolescents to consent to ATN113 participation on their own behalf when permitted under 
state law as interpreted by their local IRB; and the protocol was written to require adolescent 
self-consent. As part of routine network protocol implementation procedures, an IRB submission 
packet was provided to all sites that included an IRB submission cover letter summarizing the 
protocol, an IRB submission template and the ATN113 protocol itself. Materials specific to the 
external consultations described above were also provided. 
 
A summary of the ATN113 recruitment and consent process, as described in the protocol, 
follows. Recruitment is to be conducted using venue-based methods and/or online-based 
methods. For venue-based recruitment, potential participants are to be approached in coffee 
houses, gay youth centers, book clubs, House Ball community gatherings, parent groups and 
clinics caring for the target population. ATN study sites have the option of also using social 
networking sites and geo-social networking mobile applications to approach potential 
participants. For venue-based recruitment, verbal consent is to be obtained before screening 
potential participants for preliminary eligibility using a handheld device, and for online-based 
recruitment a web-based screener is to be used. If a participant is deemed eligible based on 
preliminary criteria, he is to be offered an in-person screening appointment at the study site. On 
the day of the in-person screening, prior to determining final eligibility, the purpose, procedures, 
requirements, risks and benefits of the study are to be thoroughly discussed with the potential 
participant and written consent obtained. Prior to screening for final eligibility, an “assessment of 
understanding” questionnaire must also to be administered to ensure understanding. 
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Study Purpose and Aims 
The specific aims of the ATN113 sub-study described in this article were to examine: (1) the 
initiation process by which ATN investigators and other study personnel, in collaboration with 
their local IRBs, evaluated the issue of adolescent self-consent and reached decisions regarding 
whether or not to approve and implement the ATN113 protocol; and (2) reflections on valuable 
lessons learned. Understanding this initiation process is critically important as new biomedical 
HIV prevention technologies, including microbicides and vaccines, continue to emerge. Lessons 
learned during this process may help guide researchers, IRB members, and policy makers in the 
responsible conduct of future biomedical HIV prevention research with minor participants who 
are at substantial risk for HIV infection.  
 
METHODS 
Qualitative Descriptive (QD) methods, which provide an in-depth description of experiences 
shared by a group facing a common challenge,17 were used to meet the sub-study’s aims. The 
QD approach is particularly useful for generating straightforward summaries of information to 
guide future intervention. It relies on purposive sampling, moderately structured interviews with 
key informants, and low-inference content analysis. This study was exempted from full review 
by the Indiana University IRB – Human Subjects. 
 
Study Population, Setting and Dates  
The study population included ATN investigators and study personnel at all sites contemplating 
implementation of ATN113. Research activities took place via phone and email between May 
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and November 2013. Verbal consent was obtained, and all informants received written 
information explaining the study’s purpose and aims.  
 
Data Collection Procedures 
Sources of data included: (1) moderately structured interviews with informants; (2) informal 
documented correspondence between informants and their respective IRBs related to ATN113 
(e.g., emails and verbal communication logs); and (3) formal IRB memoranda related to 
ATN113 (e.g., letters of approval). Digitally recorded telephone interviews were conducted by 
the first author addressing the following topics: (1) personal experience with research requiring 
minor consent, (2) perception of IRB experience with research requiring minor consent, (3) 
issues informants found to be troubling, (4) issues the IRB found to be problematic, (5) processes 
by which identified issues were addressed, (6) final IRB disposition, (7) opinions regarding the 
IRB disposition and implementation decision, and (8) lessons learned that may inform future 
studies.  
 
Data Management and Analysis 
Interviews were transcribed verbatim by a professional transcription service. Two authors (ALG 
and ASK) compared the transcripts to the audio-recordings, making corrections as needed. Data 
were uploaded to a cloud-based qualitative data analysis program (Dedoose, Hermosa Beach, 
CA, USA). Authors ALG and ASK then divided the sites into two groups and reviewed all data 
associated with each site, excerpting all text units addressing the study’s aims. Each text unit was 
coded to reflect its content, and a case-ordered meta-matrix18 was used to organize and 
summarize the data into categories and sub-categories. ALG and ASK then reconvened to select 
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exemplar segments of text illustrating each category. To protect privacy, each site was randomly 
assigned a letter to represent it in publications and presentations. 
 
RESULTS 
Seventeen informants from 13 ATN sites in 12 states participated in the study. The remaining 
ATN site did not participate for administrative reasons not related to the study. A majority of 
informants were female, White and Non-Hispanic (Table 1). The data reflect a process (Figure 1) 
by which study teams initiated ATN113, and describe the practical, ethical and legal challenges 
that arose during this process. Below, we discuss each step in the process, the challenges and 
solutions that emerged, and lessons learned along the way. Exemplary quotes are contained in 
Tables 2 and 3. 
 
ATN Initiation Process 
 
Responding to the Protocol. Informants reflected on personal responses to ATN113, describing 
feelings such as worry or enthusiasm. Most reported initial concerns that stemmed from the 
sense of responsibility they felt as providers or fear they felt as parents. From a professional 
perspective, informants reported feeling accountable to participants’ parents, and worrying about 
how parents might react if a participant experienced serious study-related side effects. Many 
were concerned about the study’s legality, and expressed anxiety about implications for their 
respective institutions. Others discussed concerns about the vulnerability of prospective 
participants. They worried that low comprehension and economic deprivation would make it 
difficult to ensure that participants were fully aware of the risks of participation and competent to 
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follow through with protocol requirements such as attending appointments, taking medications as 
prescribed, and reporting side effects. Informants also spoke about responding emotionally as 
parents, and several expressed tension between their professional and parental perspectives. A 
large majority of informants, however, reported that they were reassured as the process 
progressed. 
 
Preparing for IRB Submission. Many informants doubted that their IRB would approve 
ATN113, and all anticipated challenges during the review process. Informants characterized 
existing relationships with local IRBs as well established, positive and valuable; with several 
specifically noting IRB willingness to consider controversial or cutting edge research. Most 
reported beginning the process by giving their IRB advance notice by phone or email, leveraging 
existing relationships to initiate informal review prior to formal protocol submission. During 
these exchanges, they reported that IRB members often specified which aspects of the protocol 
would be problematic and indicated the type of documentation that would help mitigate 
concerns. Informants also attended meetings with IRB members to discuss the protocol in 
advance of submission, and educated IRB members about PrEP by collating journal articles, 
sharing previous experience with the study drug, and encouraging people to attend talks about its 
use.  
 
Informants identified the legality of minor self-consent for research participation as the issue 
they anticipated as having the most difficulty with, and conversations with IRB members 
supported this concern. Reviewing state laws relevant to minor consent was therefore a common 
activity.  Informants reported researching state statutes, interpreting them independently or with 
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the help of a consultant, and then providing this information to the IRB, either in advance of 
submission or as part of the submission package.  
 
Abstaining from or Proceeding with Submission. Informants gauged IRB responses in the 
preparatory phase, and then decided whether to proceed. Eleven sites proceeded with 
submission. Of note, one submitted the protocol despite IRB forewarning that it would be denied 
and another moved forward with submission but later withdrew the protocol upon the ATN’s 
request for administrative purposes. Two sites abstained from submission entirely, one because 
informants were advised by the IRB that it would not approve the protocol with adolescent self-
consent and the other because informants were advised by an attorney that it could not be 
approved under state law. 
 
Responding to IRB Concerns. Informants at all sites revealed IRB concerns about the informed 
consent process. These concerns included issues with the form itself (length, language, level of 
specificity); objective measurement of participant understanding; and the legality of minor self-
consent for research participation. In response, informants described editing the proposed 
consent form (in one case, with the help of a consultant to make the form more age-appropriate) 
and engaging attorney consultants to draft legal memoranda regarding legality. Informants also 
reported that IRB members believed additional protections should be provided to minor 
participants, regardless of regulatory necessity, by parents, surrogate adult decision-makers 




Informants also described IRB member concerns about the balance of the risks (e.g., coercion, 
privacy issues related to the use of social media for recruitment, and concerns about drug safety 
and drug resistance) versus the benefits of participation (e.g., behavioral counseling and 
prevention of infection). Many of these concerns were raised and addressed as completely as 
possible in the preparatory phase, but when they arose after submission, informants responded by 
engaging in discussions with IRB members and modifying the protocol when possible. Some 
IRB members expressed concern that they personally, or their institutions, might be held legally 
liable for adverse participant outcomes and sought reassurance that this would not happen. The 
legal advice solicited and provided by researchers was not always sufficient to assuage IRB 
concerns.  
 
Reacting to the Outcomes. Seven sites were ultimately granted IRB approval, three were denied 
approval and three did not receive a formal IRB disposition (Figure 2). Although various issues 
were addressed by IRBs in their formal approval and non-approval memoranda, all IRBs that 
issued formal dispositions specifically addressed the legality of minor consent with 
interpretations of state law that varied widely. For example, very similarly worded statutes in two 
states with no common law precedent for how the statutes should be interpreted came to opposite 
conclusions about the legality of adolescent consent for preventive research. 
 
Informants at all seven sites that received approval and implemented the protocol expressed 
confidence in the decisions reached by their respective IRBs, and their own decisions to 
implement. Reactions were mixed among the three sites that were denied approval; informants at 
two sites reported feeling simultaneously disappointed and relieved, while an informant at the 
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third was disappointed with the decision and ultimately decided to open a PrEP clinic for at-risk 
minors. Informants from two of three sites that did not receive a formal disposition expressed 
disappointment that they could not be involved in what they perceived to be an important trial. 
 
Reflections on Lessons Learned 
Informants reflected on lessons learned during the ATN113 initiation process and shared advice 
they believed could help other researchers with the initiation process in future studies of this 
nature. They emphasized the importance of persistence, searching for solutions to problems and 
returning to the IRB with new information. Informants also spoke of striving for collaborative 
relationships with IRB members by empathizing with their work load and responsibilities, being 
transparent in all exchanges, providing as much information as possible up front, and 
communicating in person. They advocated for identifying and engaging experts early and often. 
For example, they spoke of seeking formal or informal ethical and legal consultation, working 
closely with compliance officers, and approaching States’ Attorneys General for non-binding 
interpretations of state statutes. See Table 3. 
 
DISCUSSION 
This study examines the process by which researchers and IRBs across the nation undertook the 
difficult task of initiating a biomedical HIV prevention protocol that required high-risk minor 
youth to consent to research participation on their own behalf. The results illustrate the complex 
legal and ethical factors researchers and IRBs must consider in determining whether to conduct 
biomedical trials with this population. To place the results in context, clinical trials data from 
adult studies provide strong evidence of FTC/TDF efficacy, safety, and an acceptable range of 
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side effects; and the drug combination is already widely used for HIV treatment with 
adolescents. These realities, combined with (1) disproportionately high HIV infections rates 
among YMSM,3 (2) the fact that HIV infection itself is an incurable disease, (3) the critical need 
for safety data among youth who may well be prescribed FTC/TDF for PrEP use off-label even 
in the absence of such data,5 (4) the familial rejection and potential violence experienced by 
many YMSM,10,11 and (5) justifiable expectations of a favorable balance of risks and benefits, 
provided the ATN with a compelling rationale for conducting ATN113 without parental consent. 
Nevertheless, the study did confront researchers and IRBs with a host of ethical challenges.  
 
Ethical considerations generally revolved around the principle of respect for persons. Although 
adolescents with legal authority to consent under state law were assumed to be fully autonomous, 
careful consideration was given to adolescents’ capacity to fully understand the risks of 
participation, including the risks of failing to adhere to the study protocol. Informants also 
expressed concern about whether adolescents would have a realistic view of the medication’s 
benefits, be influenced by monetary reimbursements, and/or underestimate risks of study 
participation to health or family relationships. Thus, the provision of a legal basis for adolescent 
self-consent did not erase vulnerability from the considerations, such as risk compensation and 
preventive misconception,19,20 that inform restrictions on adolescent research participation in the 
first place.  
 
Ethical considerations also focused on the principle of beneficence and the balance of potential 
harms and benefits. The benefit of participation most often identified was the prevention of HIV. 
Identified risks included coercion and concerns about drug safety. Informants also noted that 
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privacy issues related to the use of social media for recruitment could emerge if adolescents 
inadvertently, or without sufficient consideration of the consequences, were to share information 
about the ATN113 participation on the social media tools used to recruit them. Informants also 
expressed concerns about the potential for the development of drug resistance if partially-
adherent participants were to acquire HIV, remain undiagnosed and continue taking the study 
drug intermittently, resulting in ineffective treatment for the virus. 
 
Implementation of ATN113 hinged primarily on IRB interpretations of state minor consent laws. 
While most states allow minors to consent to medical diagnosis or treatment of sexually 
transmitted infections, few expressly allow self-consent for preventive services,15 and legal 
interpretations extending the laws to prevention have not yet been tested in most state court 
systems. While some IRBs interpreted the statutory language of their respective states to include 
prevention, many did not.  
 
Informants made great efforts to better understand and educate their IRBs about their states’ 
minor consent laws, and advised future researchers to do the same. They stressed the importance 
of researching the law in advance, and engaging knowledgeable experts (ethicists, attorneys, 
compliance officers and State Attorneys General) to provide guidance that may proactively be 
shared. Our finding that two IRBs reached opposite conclusions, referencing statutory language 
that was almost exactly the same to support their divergent positions, illustrates just how widely 
interpretations of law may differ. Although it is expected and appropriate for IRB dispositions to 
vary across sites based on the cultures and values of their respective institutions and 
communities, the inconsistent application of law in this case highlights a genuine need for better-
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articulated standards regarding adolescent participation in preventive biomedical research. Such 
standards may help address procedural justice issues that directly affect adolescent access to both 
the risks and benefits of research participation.21 
 
As with all research, this study has several limitations. Informants were from major medical 
centers in large U.S. cities with well-established adolescent research programs and strong IRB 
relationships, so findings may therefore typify the initiation process at centers such as these 
rather than that experienced at smaller centers with developing programs. Also, interviews were 
conducted after IRB decisions were rendered, where applicable, and responses relied on 
informant recall. It is possible that IRB dispositions may have influenced informant perceptions; 
those whose IRBs failed to approve the protocol may have tried to rationalize the rejection by 
emphasizing challenges, whereas those from approved sites may have minimized them. A 
different, although arguably less efficient, approach may have been to collect data at several 
different points in time to minimize such interactions. This limitation was mitigated, however, by 
the collection of verbal communication logs and other communications throughout the protocol 
initiation process, and the triangulation of interviews and official IRB memoranda with these 
data. The goal of this study was to examine factors related to the process by which IRBs and 
researchers make decisions regarding whether to approve and implement biomedical HIV 
prevention studies, we elected to assess these factors primarily from the perspective of 
researchers. A more comprehensive understanding may be obtained if future studies were to 
include IRB members as engaged subjects. 
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These findings demonstrate the complex factors researchers and IRBs must consider in 
determining whether to conduct biomedical HIV prevention trials in which high-risk minor youth 
consent on their own behalf. They also clearly demonstrate that such protocols may be approved 
and implemented in situations where compelling justifications exist for not engaging parents, and 
provide guidance about how best to proceed. Researchers working with adolescents in this 
context should carefully consider relevant law, particularly in states with minor consent laws that 
do not contain language specific to prevention. They may also need to work with local 
authorities and policymakers to help educate them about adolescent research needs, and how 
various laws, regulations and policies influence the implementation of clinical trials with this 
vulnerable population. Additional standards, such as formal agency guidance or a comprehensive 
toolkit developed by the ATN in collaboration with investigators and other stakeholders at each 
of its sites, would go far in ensuring the responsible conduct of future biomedical HIV 
prevention research with minor participants.   
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